Therapeutic drug monitoring of antiarrhythmic drugs

被引:0
|
作者
Jürgens, G
Graudal, NA
Kampmann, JP
机构
[1] Copenhagen Univ Hosp, Dept Clin Pharmacol, DK-2100 Copenhagen O, Denmark
[2] Univ Copenhagen, Herlev Hosp, Dept Internal Med & Rheumatol Q, DK-2730 Herlev, Denmark
[3] Med Agcy, Inst Rat Pharmacotherapy, Copenhagen, Denmark
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Most antiarrhythmic drugs fulfil the formal requirements for rational use of therapeutic drug monitoring, as they show highly variable plasma concentration profiles at a given dose and a direct concentration-effect relationship. Therapeutic ranges for antiarrhythmic drugs are, however, often very poorly defined. Effective drug concentrations are based on small studies or studies not designed to establish a therapeutic range, with varying dosage regimens and unstandardised sampling procedures. There are large numbers of nonresponders and considerable overlap between therapeutic and toxic concentrations. Furthermore, no study has ever shown that therapeutic drug monitoring makes a significant difference in clinical outcome. Therapeutic concentration ranges for antiarrhythmic drugs as they exist today can give an overall impression about the drug concentrations required in the majority of patients. They may also be helpful for dosage adjustment in patients with renal or hepatic failure or in patients with possible toxicological or compliance problems. Their use in optimising individual antiarrhythmic therapy, however, is very limited.
引用
收藏
页码:647 / 663
页数:17
相关论文
共 50 条
  • [31] CLASSIFICATION OF ANTIARRHYTHMIC DRUGS AND THERAPEUTIC CONCLUSIONS
    SENGES, J
    HENNIG, E
    MEDIZINISCHE KLINIK, 1982, 77 (09) : 286 - 288
  • [32] Therapeutic drug monitoring of antipsychotic drugs in schizophrenic outpatients
    Tatusch, V.
    Konrad, A.
    Roeschke, J.
    Palmer, G.
    Hiemke, C.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 146 - 146
  • [33] LIGHT AND SHADE OF THERAPEUTIC DRUG MONITORING OF ANTIEPILEPTIC DRUGS
    Cojutti, P. G.
    Furlanut, M.
    Franceschi, L.
    EPILEPSIA, 2010, 51 : 25 - 25
  • [34] Rationale for therapeutic drug monitoring (TDM) of anticancer drugs
    Boddy, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2001, 15 : 8 - 8
  • [35] Therapeutic drug monitoring of oral targeted antineoplastic drugs
    Anna Mueller-Schoell
    Stefanie L. Groenland
    Oliver Scherf-Clavel
    Madelé van Dyk
    Wilhelm Huisinga
    Robin Michelet
    Ulrich Jaehde
    Neeltje Steeghs
    Alwin D.R. Huitema
    Charlotte Kloft
    European Journal of Clinical Pharmacology, 2021, 77 : 441 - 464
  • [36] Therapeutic drug monitoring of inununosuppressant drugs in clinical practice
    Kahan, BD
    Keown, P
    Levy, GA
    Johnston, A
    CLINICAL THERAPEUTICS, 2002, 24 (03) : 330 - 350
  • [37] Introduction to the therapeutic drug monitoring of antipsychotic and antidepressant drugs
    Ulrich, S
    Schrödter, I
    Partscht, G
    Baumann, P
    PSYCHOPHARMAKOTHERAPIE, 2000, 7 (01): : 2 - +
  • [38] Therapeutic drug monitoring of anti-HIV drugs
    Back, DJ
    Khoo, SH
    Gibbons, SE
    Reynolds, H
    Tjia, JF
    Merry, C
    OPTIMAL DOSE IDENTIFICATION: EXCERTA MEDICA, 2001, 1220 : 145 - 160
  • [39] Current opinions on therapeutic drug monitoring of immunosuppressive drugs
    Shaw, LM
    Holt, DW
    Keown, P
    Venkataramanan, R
    Yatscoff, RW
    CLINICAL THERAPEUTICS, 1999, 21 (10) : 1632 - 1652
  • [40] Therapeutic drug monitoring of anti-tuberculous drugs
    Simpson, G
    Konstantinos, A
    INTERNAL MEDICINE JOURNAL, 2004, 34 (1-2) : 74 - 75